BrightPath Biotherapeutics Co., Ltd. (TYO:4594)

Japan flag Japan · Delayed Price · Currency is JPY
69.00
+6.00 (9.52%)
Mar 6, 2026, 3:30 PM JST
Market Cap9.09B +141.7%
Revenue (ttm)1.11M -99.6%
Net Income-1.08B
EPS-11.35
Shares Out131.77M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume12,435,800
Average Volume8,532,300
Open64.00
Previous Close63.00
Day's Range64.00 - 72.00
52-Week Range32.00 - 114.00
Beta1.63
RSI56.54
Earnings DateFeb 13, 2026

About TYO:4594

BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I clinical trial to target cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers. In addition, its product candidates in preclinical trials include BP1200 that targets CD73; BP1202 that targets CD39; BP1210, which su... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 42
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4594
Full Company Profile

Financial Performance

In fiscal year 2025, TYO:4594's revenue was 1.13 million, an increase of 1473.61% compared to the previous year's 72,000. Losses were -1.15 billion, -1.45% less than in 2024.

Financial Statements